[go: up one dir, main page]

NO20074641L - 1-Acetic Acid-Indole Derivatives with PGD2 Antagonist Activity - Google Patents

1-Acetic Acid-Indole Derivatives with PGD2 Antagonist Activity

Info

Publication number
NO20074641L
NO20074641L NO20074641A NO20074641A NO20074641L NO 20074641 L NO20074641 L NO 20074641L NO 20074641 A NO20074641 A NO 20074641A NO 20074641 A NO20074641 A NO 20074641A NO 20074641 L NO20074641 L NO 20074641L
Authority
NO
Norway
Prior art keywords
acetic acid
antagonist activity
indole derivatives
alkyl
pgd2
Prior art date
Application number
NO20074641A
Other languages
English (en)
Inventor
Edward Andrew Boyd
Richard Edward Armer
Philip Andrew Hay
Original Assignee
Oxagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxagen Ltd filed Critical Oxagen Ltd
Publication of NO20074641L publication Critical patent/NO20074641L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives forbindelser med den generelle formel (I) der Rer halo eller cyano; Rer C_-alkyl; og Rer fenyl substituert med en eller flere substituenter valgt blant Ci_-i alkyl, halo eller -S0(C.-alkyl); eller et farmasøytisk akseptabelt salt, hydrat, solvat, kompleks eller prodmg derav.Forbindelsene er nyttige ved terapi av sykdommer og tilstander som medieres av virkningen av PGDpå CRTH2-reseptoren.
NO20074641A 2005-03-11 2007-09-12 1-Acetic Acid-Indole Derivatives with PGD2 Antagonist Activity NO20074641L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0505048.9A GB0505048D0 (en) 2005-03-11 2005-03-11 Compounds with PGD antagonist activity
PCT/GB2006/000851 WO2006095183A1 (en) 2005-03-11 2006-03-10 1-acetic acid-indole derivatives with pgd2 antagonist activity

Publications (1)

Publication Number Publication Date
NO20074641L true NO20074641L (no) 2007-11-01

Family

ID=34508918

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074641A NO20074641L (no) 2005-03-11 2007-09-12 1-Acetic Acid-Indole Derivatives with PGD2 Antagonist Activity

Country Status (26)

Country Link
US (1) US8044088B2 (no)
EP (1) EP1856045B1 (no)
JP (1) JP2008532990A (no)
KR (1) KR20070116633A (no)
CN (1) CN101166721A (no)
AT (1) ATE442356T1 (no)
AU (1) AU2006221784A1 (no)
BR (1) BRPI0608732A2 (no)
CA (1) CA2601980A1 (no)
CY (1) CY1109532T1 (no)
DE (1) DE602006009080D1 (no)
DK (1) DK1856045T3 (no)
ES (1) ES2333161T3 (no)
GB (1) GB0505048D0 (no)
HR (1) HRP20090654T1 (no)
IL (1) IL185844A0 (no)
MX (1) MX2007011091A (no)
NO (1) NO20074641L (no)
NZ (1) NZ561747A (no)
PL (1) PL1856045T3 (no)
PT (1) PT1856045E (no)
RS (1) RS51016B (no)
RU (1) RU2007134456A (no)
SI (1) SI1856045T1 (no)
WO (1) WO2006095183A1 (no)
ZA (1) ZA200708159B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
DK2037967T3 (en) 2006-06-16 2017-03-13 Univ Pennsylvania PROSTAGLANDIN-D2 RECEPTOR ANTAGONISTS FOR TREATMENT OF ANDROGENETIC ALOPECI
DK2046740T3 (da) * 2006-07-22 2012-08-20 Oxagen Ltd Forbindelser med CRTH2-antagonistisk virkning
HRP20120044T1 (hr) 2006-08-07 2012-02-29 Actelion Pharmaceuticals Ltd. Derivati (3-amino-1,2,3,4-tetrahidro-9h-karbazol-9-il)-octene kiseline
GB0722203D0 (en) * 2007-11-13 2007-12-19 Oxagen Ltd Use of CRTH2 antagonist compounds
GB0722216D0 (en) * 2007-11-13 2007-12-27 Oxagen Ltd Use of crth2 antagonist compounds
PL2327693T3 (pl) * 2007-12-14 2012-11-30 Pulmagen Therapeutics Asthma Ltd Indole i ich zastosowanie terapeutyczne
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
AU2009204700B2 (en) * 2008-01-18 2013-07-04 Atopix Therapeutics Limited Compounds having CRTH2 antagonist activity
JP2011509991A (ja) * 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
US8470594B2 (en) * 2008-04-15 2013-06-25 President And Fellows Of Harvard College Methods for identifying agents that affect the survival of motor neurons
US9180114B2 (en) 2008-11-26 2015-11-10 President And Fellows Of Harvard College Neurodegenerative diseases and methods of modeling
AU2010218209B2 (en) * 2009-02-24 2012-12-13 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
US8697869B2 (en) 2010-03-22 2014-04-15 Actelion Pharmaceuticals Ltd. 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivatives and their use as prostaglandin D2 receptor modulators
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
SG193902A1 (en) 2011-04-14 2013-11-29 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
PT2781508T (pt) * 2011-11-17 2019-03-20 Kbp Biosciences Co Ltd Compostos de anel fundido contendo azoto para utilização como antagonistas de crth2
GB201121557D0 (en) 2011-12-15 2012-01-25 Oxagen Ltd Process
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
WO2014066568A1 (en) 2012-10-24 2014-05-01 Winthrop-University Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
KR102116978B1 (ko) 2013-10-07 2020-05-29 삼성전자 주식회사 그래핀 소자 및 그 제조 방법
GB201322273D0 (en) * 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
UA117780C2 (uk) 2014-03-17 2018-09-25 Ідорсія Фармасьютікалз Лтд Похідні азаіндолоцтової кислоти та їх застосування як модуляторів рецепторів простагландину d2
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
ES2991300T3 (es) 2015-02-13 2024-12-03 Inserm Institut Nat De La Sante Et De Larecherche Medicale Antagonistas de PTGDR-1 y/o PTGDR-2 para prevenir y/o tratar lupus eritematoso sistémico
HK1256553A1 (zh) 2015-07-30 2019-09-27 The Trustees Of The University Of Pennsylvania 用於检测pgd2对毛发生长抑制的易感性的人dp-2基因的单核苷酸多态性等位基因
MX379014B (es) 2015-09-15 2025-03-10 Idorsia Pharmaceuticals Ltd Formas cristalinas.
CA3075688A1 (en) 2017-09-13 2019-03-21 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
CN109180691B (zh) * 2018-08-24 2020-07-10 武汉大学 一种c3-芳香型吡咯并吲哚类生物碱及其合成方法
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
CN113425714B (zh) * 2021-08-04 2022-04-26 华南师范大学 吲哚乙酸在制备防治慢性阻塞性肺病药物中的应用
CN114870018A (zh) * 2022-05-12 2022-08-09 江南大学 炎症小体nlrp3抑制剂通过抑制神经系统炎症在制备治疗阿尔茨海默症药物中的应用
WO2024192765A1 (en) * 2023-03-23 2024-09-26 Brown University First in class use of the crth2 antagonist in treating neuromyelitis optica spectrum disorder (nmosd) and relevant autoimmune cns disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641800A (en) * 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
KR100584650B1 (ko) * 1998-03-31 2006-05-30 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 치환된 인돌알칸산
WO2003097598A1 (en) * 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
TW200307542A (en) * 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0302232D0 (sv) * 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
GB0504150D0 (en) * 2005-03-01 2005-04-06 Oxagen Ltd Microcrystalline material
DK2046740T3 (da) * 2006-07-22 2012-08-20 Oxagen Ltd Forbindelser med CRTH2-antagonistisk virkning
PL2327693T3 (pl) 2007-12-14 2012-11-30 Pulmagen Therapeutics Asthma Ltd Indole i ich zastosowanie terapeutyczne
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
JP2011509991A (ja) * 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
JP2011509990A (ja) * 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物

Also Published As

Publication number Publication date
CY1109532T1 (el) 2014-08-13
ZA200708159B (en) 2009-11-25
HRP20090654T1 (hr) 2010-01-31
EP1856045B1 (en) 2009-09-09
ES2333161T3 (es) 2010-02-17
BRPI0608732A2 (pt) 2016-11-08
IL185844A0 (en) 2008-01-06
US20100330077A1 (en) 2010-12-30
SI1856045T1 (sl) 2010-01-29
AU2006221784A1 (en) 2006-09-14
PL1856045T3 (pl) 2010-02-26
CN101166721A (zh) 2008-04-23
EP1856045A1 (en) 2007-11-21
DK1856045T3 (da) 2010-01-04
WO2006095183A1 (en) 2006-09-14
JP2008532990A (ja) 2008-08-21
PT1856045E (pt) 2009-12-09
GB0505048D0 (en) 2005-04-20
CA2601980A1 (en) 2006-09-14
RS51016B (sr) 2010-10-31
DE602006009080D1 (de) 2009-10-22
RU2007134456A (ru) 2009-04-20
MX2007011091A (es) 2007-11-22
ATE442356T1 (de) 2009-09-15
NZ561747A (en) 2010-03-26
KR20070116633A (ko) 2007-12-10
US8044088B2 (en) 2011-10-25
HK1109628A1 (en) 2008-06-13

Similar Documents

Publication Publication Date Title
NO20074641L (no) 1-Acetic Acid-Indole Derivatives with PGD2 Antagonist Activity
PE20091005A1 (es) N-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas
NO20070532L (no) Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
TW200637550A (en) Thiazole-4-carboxamide derivatives as mGluR5 antagonists
NO20091409L (no) Pyridin-3-yl-derivater som immunmodulerende midler
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
DE60317326D1 (de) Phenylalkansäure- und phenyloxyalkansäure-derivate als hppar aktivatore
GB0510584D0 (en) Organic compounds
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
NO20075734L (no) Tiofenforbindelser og trombopoietin reseptoractivatorer
NO20071319L (no) Fremgangsmate for fremstilling av isotiazolderivater.
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
AR076362A1 (es) Arilsulfonamidas 2,5-disustituidas antagonistas de ccr3, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento y/o prevencion de patologias autoinmunes e inflamatorias, entre otras.
NO20072684L (no) Konjugater med anti-inflammatorisk aktivitet
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы
CO6321159A2 (es) Compuestos pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias
DE602004026558D1 (de) Selektive nichtsteroidale glucocorticoid-rezeptor- modulatoren
CY1112638T1 (el) Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsον
NO20090332L (no) 4-amino-3-arylamino-6-arylpyrazol[3,4-D]pyrimidinderivater, fremgangsmater for deres fremstilling og dere anvendelse som antivirale midler
NO20071230L (no) Oksazolidinoner inneholdende oksindoler som antibakterielle midler
NO20081529L (no) Naftyridinderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application